Uppsala Monitoring Centre: Difference between revisions

From WikiMD's Wellness Encyclopedia

Newer edit →
CSV import
 
CSV import
Line 1: Line 1:
'''Uppsala Monitoring Centre''' (UMC) is a global [[pharmacovigilance]] centre located in [[Uppsala]], [[Sweden]]. It is an independent foundation that works to advance the science of pharmacovigilance and improve patient safety worldwide.
== Uppsala Monitoring Centre ==


== History ==
[[File:Uppsala_Monitoring_Centre_facade_logo.jpg|thumb|Logo of the Uppsala Monitoring Centre]]


The UMC was established in 1978 by the [[World Health Organization]] (WHO) as a response to the [[Thalidomide]] disaster in the 1960s. The centre was set up to monitor the safety of medicines and to promote rational use of drugs in member countries.
The '''Uppsala Monitoring Centre''' (UMC) is an independent, non-profit foundation and a centre for international service and scientific research in the field of [[pharmacovigilance]]. It is located in [[Uppsala]], [[Sweden]]. UMC was established in 1978 to support the [[World Health Organization]]'s (WHO) Programme for International Drug Monitoring.


== Role and Function ==
== History ==
 
The UMC's primary role is to manage the [[WHO Programme for International Drug Monitoring]], which collects and analyses reports of suspected adverse drug reactions from over 130 member countries. The centre maintains the largest database of its kind in the world, known as [[VigiBase]], which contains over 20 million reports of suspected adverse drug reactions.
 
The UMC also provides training and support to national pharmacovigilance centres, conducts research into drug safety, and develops tools and guidelines to support pharmacovigilance activities worldwide.
 
== VigiBase ==


VigiBase is the global database for individual case safety reports (ICSRs), managed by the UMC. It is the largest database of its kind, containing reports from over 130 countries. The database is used to detect signals of potential safety issues with medicines, which can then be investigated further.
The Uppsala Monitoring Centre was founded in 1978 as a result of a WHO initiative to create a global system for monitoring the safety of medicines. The centre was established in Uppsala, Sweden, due to the country's strong tradition in [[pharmaceutical]] research and development. Since its inception, UMC has played a crucial role in collecting and analyzing data on adverse drug reactions (ADRs) from around the world.


== Signal Detection ==
== Functions ==


One of the key functions of the UMC is [[signal detection]]. This involves analysing data from VigiBase to identify new or changing safety issues with medicines. The UMC uses a range of statistical methods and algorithms to detect signals, and publishes its findings in the [[WHO Pharmaceuticals Newsletter]].
UMC's primary function is to manage the [[WHO Programme for International Drug Monitoring]], which involves collecting and analyzing reports of adverse drug reactions from member countries. The centre maintains the [[VigiBase]], the largest global database of ADRs, which is used to identify potential safety issues with medicines. UMC also develops tools and methodologies for signal detection and risk assessment in pharmacovigilance.


== Training and Support ==
== Research and Development ==


The UMC provides training and support to national pharmacovigilance centres around the world. This includes training in signal detection, data management, and the use of VigiBase. The centre also develops tools and guidelines to support pharmacovigilance activities.
UMC is involved in various research projects aimed at improving the safety of medicines. The centre collaborates with academic institutions, regulatory authorities, and the pharmaceutical industry to advance the science of pharmacovigilance. UMC also provides training and education to healthcare professionals and regulatory staff worldwide.


== Research ==
== Global Impact ==


The UMC conducts research into drug safety and pharmacovigilance. This includes studies into the causes and prevention of adverse drug reactions, the effectiveness of pharmacovigilance systems, and the use of real-world data in drug safety research.
The work of UMC has had a significant impact on global public health by improving the safety of medicines. The centre's efforts have led to the identification of numerous safety signals, resulting in changes to drug labels, withdrawal of unsafe medicines, and the development of safer therapeutic alternatives.


== See Also ==
== Related Pages ==


* [[Pharmacovigilance]]
* [[Pharmacovigilance]]
Line 33: Line 27:
* [[Adverse drug reaction]]
* [[Adverse drug reaction]]
* [[VigiBase]]
* [[VigiBase]]
* [[Signal detection]]
 
== References ==
 
{{Reflist}}


[[Category:Pharmacovigilance]]
[[Category:Pharmacovigilance]]
[[Category:Medical and health organisations based in Sweden]]
[[Category:World Health Organization]]
[[Category:World Health Organization]]
[[Category:Drug safety]]
[[Category:Organizations based in Uppsala]]
 
[[Category:Organizations established in 1978]]
{{pharmacology-stub}}

Revision as of 16:12, 9 February 2025

Uppsala Monitoring Centre

Logo of the Uppsala Monitoring Centre

The Uppsala Monitoring Centre (UMC) is an independent, non-profit foundation and a centre for international service and scientific research in the field of pharmacovigilance. It is located in Uppsala, Sweden. UMC was established in 1978 to support the World Health Organization's (WHO) Programme for International Drug Monitoring.

History

The Uppsala Monitoring Centre was founded in 1978 as a result of a WHO initiative to create a global system for monitoring the safety of medicines. The centre was established in Uppsala, Sweden, due to the country's strong tradition in pharmaceutical research and development. Since its inception, UMC has played a crucial role in collecting and analyzing data on adverse drug reactions (ADRs) from around the world.

Functions

UMC's primary function is to manage the WHO Programme for International Drug Monitoring, which involves collecting and analyzing reports of adverse drug reactions from member countries. The centre maintains the VigiBase, the largest global database of ADRs, which is used to identify potential safety issues with medicines. UMC also develops tools and methodologies for signal detection and risk assessment in pharmacovigilance.

Research and Development

UMC is involved in various research projects aimed at improving the safety of medicines. The centre collaborates with academic institutions, regulatory authorities, and the pharmaceutical industry to advance the science of pharmacovigilance. UMC also provides training and education to healthcare professionals and regulatory staff worldwide.

Global Impact

The work of UMC has had a significant impact on global public health by improving the safety of medicines. The centre's efforts have led to the identification of numerous safety signals, resulting in changes to drug labels, withdrawal of unsafe medicines, and the development of safer therapeutic alternatives.

Related Pages

References

<references group="" responsive="1"></references>

Retrieved from "https://wikimd.com/index.php?title=Uppsala_Monitoring_Centre&oldid=6200333"